Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma regains China rights to Nerlynx and amends deal with Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Accord entre Pierre Fabre et Puma Biotechnology
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Partners of the Pierre Fabre Group: from health to beauty
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma regains China rights to Nerlynx and amends deal with Fabre
